MedTrace Logo

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

NCT04679948 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-08-14

Study results available
· View outcomes & findings →

Summary

The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.

Conditions

  • Healthy

Interventions

DRUG

Percoffedrinol®

Tablet

DRUG

Coumadin®

Tablet

DRUG

Antra MUPS®

Gastro-resistant tablet

DRUG

Midazolam-ratiopharm®

Oral solution

DRUG

BI 730357

Film-coated tablet

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-03-17
Completion
2021-03-17
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679948 on ClinicalTrials.gov